Loading clinical trials...
Loading clinical trials...
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.
Conditions
Interventions
Tulisokibart
Placebo
Locations
4
United States
Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120)
Tucson, Arizona, United States
Arthritis and Rheumatism Associates - Rockville ( Site 5127)
Rockville, Maryland, United States
Altoona Center for Clinical Research ( Site 5110)
Duncansville, Pennsylvania, United States
Greater Houston Rheumatology ( Site 5103)
Houston, Texas, United States
Start Date
April 20, 2026
Primary Completion Date
August 13, 2027
Completion Date
January 11, 2030
Last Updated
April 27, 2026
NCT07536529
NCT07295509
NCT07286058
NCT06100744
NCT04402086
NCT06888193
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions